{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:38:45Z","timestamp":1766579925902,"version":"3.41.2"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nucl. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Fibrodysplasia Ossificans Progressiva (FOP) is a rare, genetic disease in which heterotopic bone is formed in muscles, tendons and ligaments throughout the body. Disease progression is variable over time and between individuals. <jats:sup>18<\/jats:sup>F-fluoride uptake in newly formed bone can be evaluated using [<jats:sup>18<\/jats:sup>F]NaF (i.e., sodiumfluoride) PET\/CT, identifying active areas of bone formation in FOP. The purpose of this study was to assess the performance of various semi-quantitative methods with full kinetic analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven patients (age range: 20\u201331 years) with FOP underwent dynamic [<jats:sup>18<\/jats:sup>F]NaF scans at baseline and after one year. [<jats:sup>18<\/jats:sup>F]NaF uptake was measured in aorta descendens, vertebrae, heterotopic bone lesions and metabolically active regions on PET, and quantified using nonlinear regression (NLR) analysis together with standardized uptake value (SUV) and target-to-blood ratio (TBR). SUV was on measured the 40\u201345\u2005min frame of the dynamic sequence (SUV<jats:sup>40\u201345<\/jats:sup>) and on the subsequent static sweep (SUV<jats:sup>Static<\/jats:sup>). Correlations between and SUV<jats:sup>40\u201345<\/jats:sup> and NLR-derived <jats:italic>K<jats:sub>i<\/jats:sub><\/jats:italic> were comparable when normalized to body weight (<jats:italic>r<\/jats:italic>\u2009=\u20090.81, 95% CI 0.64\u20130.90), lean body mass (<jats:italic>r<\/jats:italic>\u2009=\u20090.79, 95% CI 0.61\u20130.89) and body surface area (<jats:italic>r<\/jats:italic>\u2009=\u20090.84, 95% CI 0.70\u20130.92). Correlation between TBR<jats:sup>40\u201345<\/jats:sup> and NLR-derived <jats:italic>K<jats:sub>i<\/jats:sub><\/jats:italic> (<jats:italic>r<\/jats:italic>\u2009=\u20090.92, 95% CI 0.85\u20130.96) was higher than for SUV<jats:sup>40\u201345<\/jats:sup>. Correlation between TBR<jats:sup>40\u201345<\/jats:sup> and NLR-derived <jats:italic>K<jats:sub>i<\/jats:sub><\/jats:italic> was similar at baseline and after one year (<jats:italic>r<\/jats:italic>\u2009=\u20090.93 and 0.94). The change in TBR<jats:sup>40\u201345<\/jats:sup> between baseline measurement and after one year correlated best with the change in NLR-derived <jats:italic>K<jats:sub>i<\/jats:sub><\/jats:italic> in the PET-active lesions (<jats:italic>r<\/jats:italic>\u2009=\u20090.87).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present data supports the use of TBR for assessing fluoride uptake in PET-active lesions in FOP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p>Sub-study of the Lumina-1 trial (<jats:ext-link>clinicaltrials.gov<\/jats:ext-link>, NCT03188666, registered 13-06-2017).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnume.2024.1406947","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:59:11Z","timestamp":1721624351000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Performance of simplified methods for quantification of [18F]NaF uptake in fibrodysplasia ossificans progressiva"],"prefix":"10.3389","volume":"4","author":[{"given":"Ruben Daniel","family":"de Ruiter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esm\u00e9e","family":"Botman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd P.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriaan Anthonius","family":"Lammertsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter G.","family":"Raijmakers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar A.","family":"Schwarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakko A.","family":"Nieuwenhuijzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinko","family":"Gonzalez Trotter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth Marelise W.","family":"Eekhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maqsood","family":"Yaqub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-021-01983-2","article-title":"Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization","volume":"16","author":"Pignolo","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13023-019-1068-7","article-title":"Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes","volume":"14","author":"Pignolo","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/jci37412","article-title":"The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization","volume":"119","author":"Shen","year":"2009","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.14740\/jocmr2465w","article-title":"The diversity of the clinical phenotypes in patients with fibrodysplasia ossificans progressiva","volume":"8","author":"Al Kaissi","year":"2016","journal-title":"J Clin Med Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/humu.20868","article-title":"Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1","volume":"30","author":"Kaplan","year":"2009","journal-title":"Hum Mutat"},{"key":"B6","doi-asserted-by":"publisher","first-page":"732728","DOI":"10.3389\/fendo.2021.732728","article-title":"Fibrodysplasia ossificans progressiva: what have we achieved and where are we now? Follow-up to the 2015 Lorentz workshop","volume":"12","author":"de Ruiter","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2019.03.009","article-title":"Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: an [18F]NaF PET\/CT study","volume":"124","author":"Botman","year":"2019","journal-title":"Bone"},{"key":"B8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.2728","article-title":"The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment","volume":"31","author":"Pignolo","year":"2016","journal-title":"J Bone Miner Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e42614","DOI":"10.7759\/cureus.42614","article-title":"Novel therapeutic targets for fibrodysplasia ossificans progressiva: emerging strategies and future directions","volume":"15","author":"Shaikh","year":"2023","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/ORR.S337491","article-title":"Monitoring and management of fibrodysplasia ossificans progressiva: current perspectives","volume":"14","author":"Smilde","year":"2022","journal-title":"Orthop Res Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bone.2017.04.015","article-title":"A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP)","volume":"101","author":"Kaplan","year":"2017","journal-title":"Bone"},{"key":"B12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/jbmr.4492","article-title":"Plasma-soluble biomarkers for fibrodysplasia ossificans progressiva (FOP) reflect acute and chronic inflammatory states","volume":"37","author":"Pignolo","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jtemb.2016.10.001","article-title":"Trace element and cytokine concentrations in patients with fibrodysplasia ossificans progressiva (FOP): a case control study","volume":"39","author":"Hildebrand","year":"2017","journal-title":"J Trace Elem Med Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bone.2017.08.012","article-title":"[18f]NaF PET\/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva","volume":"109","author":"Eekhoff","year":"2018","journal-title":"Bone"},{"key":"B15","first-page":"633","article-title":"Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET","volume":"33","author":"Hawkins","year":"1992","journal-title":"J Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/MNM.0b013e3283452918","article-title":"Validation of new image-derived arterial input functions at the aorta using 18F-fluoride positron emission tomography","volume":"32","author":"Puri","year":"2011","journal-title":"Nucl Med Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.2967\/jnumed.113.135269","article-title":"Quantification of 18F-fluoride kinetics: evaluation of simplified methods","volume":"55","author":"Raijmakers","year":"2014","journal-title":"J Nucl Med"},{"key":"B18","first-page":"3536","article-title":"Iterative image reconstruction using geometrically ordered subsets with list-mode data","author":"Popescu","year":"2004"},{"key":"B19","first-page":"1970","article-title":"Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET","volume":"38","author":"Schiepers","year":"1997","journal-title":"J Nucl Med"},{"key":"B20","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2967\/jnumed.115.154385","article-title":"PET assessment of vascular inflammation and atherosclerotic plaques: SUV or TBR?","volume":"56","author":"Chen","year":"2015","journal-title":"J Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/jbmr.2848","article-title":"Cellular hypoxia promotes heterotopic ossification by amplifying BMP signaling","volume":"31","author":"Wang","year":"2016","journal-title":"J Bone Miner Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.febslet.2012.04.030","article-title":"BMP signaling in vascular diseases","volume":"586","author":"Cai","year":"2012","journal-title":"FEBS Lett"}],"container-title":["Frontiers in Nuclear Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2024.1406947\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T09:04:41Z","timestamp":1728291881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2024.1406947\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":24,"alternative-id":["10.3389\/fnume.2024.1406947"],"URL":"https:\/\/doi.org\/10.3389\/fnume.2024.1406947","relation":{},"ISSN":["2673-8880"],"issn-type":[{"type":"electronic","value":"2673-8880"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"article-number":"1406947"}}